SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three
New Data Continue to Show OXi4503 has Significant Potential as New Treatment for AML OXi4503 Recently Prioritized as Lead Drug Development Program at Mateon SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company
Company to terminate FOCUS study due to lack of clear efficacy signal in the third interim analysis Company to reduce headcount, concentrate on OXi4503 for acute myeloid leukemia (AML) SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 19 th
Primary Endpoint - Early Progression Free Survival data favors CA4P CA4P continues to be safe and well-tolerated Next interim analysis expected in September SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing
SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the
Recruitment rate significantly increased following initial positive interim analysis Interim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
Two patients of four (50%) achieved a complete remission No dose-limiting toxicities observed SOUTH SAN FRANCISCO, Calif. , July 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan
CA4P in combination with anti-CTLA-4 antibodies resulted in 77% reduction in tumor size compared to anti-CTLA-4 antibodies alone and 89% reduction compared to control Survival benefit observed for animals receiving combination therapy SOUTH SAN FRANCISCO, Calif.
Interim Analyses for Key FOCUS Study Expected in August 2017 and September 2017 Investigator-Sponsor Pauses Enrollment in PAZOFOS Study in U.K. SOUTH SAN FRANCISCO, Calif. , June 12, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular
